The Galaxy Watch8 GLP-1 study is Samsung’s latest signal that smartwatches are being pulled deeper into medical-adjacent health research.
Samsung Electronics America and Massachusetts General Hospital are launching a six-month study around GLP-1RA therapy. That is the drug class behind treatments such as Ozempic and Wegovy.
The research will test Galaxy Watch8 and Samsung Health data in a specific way. Samsung wants to see whether the data can help clinicians monitor muscle loss while patients start weight-loss medication.
The study matters because GLP-1 use is no longer niche. Samsung cites a KFF survey showing nearly one in five U.S. adults say they have taken a GLP-1 drug. As more people use those medicines, tracking weight alone may not tell the full story.
What Samsung and MGH are testing
Under Dr. Melissa Putman at the MGH Diabetes Research Center, the study will compare adults beginning GLP-1 treatment. One group will use Galaxy Watch8 to track body composition through bioelectrical impedance analysis. It will also track activity levels, heart rate and tailored exercise guidance.
Another group will receive the standard guidance given to patients starting GLP-1RA therapy. Researchers will also use clinical-grade DXA scans to measure body composition changes.
That is the important check here. Samsung is not saying the watch replaces medical testing. It is testing whether wearable data can add useful day-to-day context between clinical visits.
Why it is a bigger wearable story
For Samsung, the pitch is broader than one drug category. Galaxy Watch has already become part of several health studies. This one pushes the device toward a more specific treatment-monitoring role.
That fits the wider wearable trend we have seen with devices such as Oura and smart rings. Consumer hardware is being judged less by novelty and more by whether its health data stays useful over time.
There are still clear limits. This is research, not a public feature rollout. It is also not a medical claim that Galaxy Watch8 can prevent muscle loss.
Users should also remember that body composition readings from wearables can vary, especially compared with clinical tools. Still, the direction is interesting. If Samsung and MGH can show that wearable data flags changes earlier, smartwatches may become more useful companions for long-term treatment plans.
